Amigrenin, pills 50mg, 2pcs

Composition

of 1 tab. sumatriptan (as succinate) 0.05 g

Auxiliary substances:

MCC;

milk sugar;

potato starch;

sodium carboxymethyl starch;

magnesium stearic acid;

oxypropylcellulose or oxypropylmethylcellulose;

PVP;

polyethylene glycol 4000;

talc;

titanium dioxide

Pharmacological action

It interacts with 5-hydroxytryptamine type 1 receptors located in the smooth muscle of the blood vessel walls of the brain.

Stimulation of 5HT1receptors leads to selective vasoconstriction in the carotid artery system and a decrease in neurogenic inflammation, without significantly affecting the cerebral blood flow. In addition, it has been experimentally established that sumatriptan inhibits the activity of the trigeminal nerve.

Selectively narrows blood vessels in the carotid artery system, inhibits the activity of the trigeminal nerve. Helps to reduce the severity of pain in migraines. The clinical effect is noted after 30 minutes.

Pharmacokinetics

Suction

When taking the drug orally, sumatriptan is rapidly absorbed from the gastrointestinal tract, after 45 minutes its plasma concentration reaches 70% of the_maximum. Absolute oral bioavailability due to presystemic metabolism and incomplete absorption is on average 14%.

Distribution

Binding to plasma proteins is 14-21%.

Metabolism

Biotransformed with the formation of metabolites, the main of which is the indoleacetic analog of sumatriptan.

The elimination

of T_1/2 is 2 hours. The main metabolite of sumatriptan is mainly excreted in the urine as a free acid or glucuronide conjugate

Indications

Relief of acute migraine attacks, with or without aura.

Use during pregnancy and lactation

The drug is contraindicated for use during pregnancy and lactation (breastfeeding).

Use in children

The drug is contraindicated in children and adolescents under 18 years of age.

Contraindications

Individual drug intolerance, CHD, including angina, hemiplegic, basilar or ophthalmoplegic forms of migraines, occlusive diseases of the peripheral arteries, uncontrolled arterial hypertension, stroke or transient cerebrovascular accident in the anamnesis, liver failure, pregnancy, breast-feeding, childhood, elderly age (over 65 years), simultaneous use with ergotamine and its derivatives.

With caution — epilepsy (including any conditions with a reduced epileptic threshold), arterial hypertension (controlled), simultaneous use of MAO inhibitors and a period of up to 14 days after their withdrawal.

Side effects

Sensation of tingling, heat, heaviness, pressure in various parts of the body, hyperemia of the skin and mucous membranes; dizziness, fatigue, weakness, drowsiness; angina attack, hypotension, tachycardia, palpitation, transient increase in blood pressure, transient ECG changes of the ischemic type, bradycardia, in isolated cases — Raynaud’s syndrome; abdominal discomfort, dysphagia, nausea, vomiting, ischemic colitis; disorders of the blood pressure system. vision disorders (diplopia, scotoma, decreased visual acuity); allergic reactions (rash, urticaria, pruritus, erythema, anaphylaxis); changes in liver function tests; myalgia.

Interaction

Concomitant use of drugs containing ergot alkaloids, lithium preparations, serotonin reuptake inhibitors, and MAO inhibitors is unacceptable.

Long-term vasospasm was observed when taken concomitantly with ergotamine. Amigrenine can be prescribed no earlier than 24 hours after taking medications containing ergotamine.

How to take, course of use and dosage

Amigrenin is not intended for use for prevention purposes.

Adults are prescribed a single dose of 50 mg, in some cases-100 mg. The maximum daily dose is 300 mg.

If the symptoms of migraine do not disappear and do not decrease after taking the first dose of Amigrenine, then the drug should not be re-prescribed to stop the ongoing attack. If symptoms have subsided or subsided and then resumed, you can take a second dose within the next 24 hours. The interval between doses of the drug should be at least 2 hours.

Overdose

Symptoms:

increased side effects.

Treatment:

in case of overdose, the patient should be monitored for 10 hours, carrying out symptomatic therapy as necessary.

Special instructions

When prescribing Amigrenine to patients with newly diagnosed migraines or migraines with atypical symptoms, other potentially dangerous neurological diseases should be excluded. It should be borne in mind that patients with migraines are at risk of developing cerebrovascular complications (including stroke or transient cerebral circulatory disorders).

The drug should not be prescribed to patients who are at risk of developing pathology from the cardiovascular system, without a preliminary examination to exclude the disease. The first 2-3 doses of the drug should be carried out under the supervision of a doctor (since spasm of the coronary arteries is possible).

Patients with hypersensitivity to sulfonamides may develop allergic reactions when taking Amigrenine, which range from skin manifestations to anaphylactic shock.

If there is no effect on the first dose, the diagnosis should be clarified.

Clinical experience with the drug in patients over the age of 65 years is limited (there is no significant difference in pharmacokinetics compared to younger patients).

Influence on the ability to drive motor vehicles and manage mechanisms

Drowsiness may occur during Amigrenin therapy. Therefore, during the period of use of the drug, patients should drive with extreme caution and engage in other potentially dangerous activities that require a high rate of psychomotor reactions.

Form of production

of Amigrenin. Film-coated tablets

Storage conditions

The drug should be stored in a dry place, protected from light. Keep out of reach of children.

Shelf

life is 2 years.

Active ingredient

Sumatriptan

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults under 65 years of age as prescribed by a doctor, For adults as prescribed by a doctor

Indications

Migraine